Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.

Dominic Pizzarella, Amanda Kofides, Xia Liu, John Hatcher, Alberto Guijosa, Nickolas Tsakmaklis, Abigail Peachey, Jinhua Wang, Maria Luisa Guerrera, Christopher Patterson, Zachary Hunter, Hao Sun, Shayna Sarosiek, Jorge Castillo, Sara Buhrlage, Sirano Dhe-Paganon, Steven Treon, Shirong Liu

Blood (2025) 146 (Supplement 1): 7453.

https://doi.org/10.1182/blood-2025-7453

Published: 2025

Journal Articles

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Alberto Guijosa, Nickolas Tsakmaklis, Sirano Dhe-Paganon, John Hatcher, Andres Ramirez, Dominic Pizzarella, Amanda Kofides, Abigail Peachey, Shirong Liu, Hao Sun, Xia Liu, Maria Luisa Guerrera, Andrew Branagan, Gottfried von Keudell, Shayna Sarosiek, Jorge Castillo, Zachary Hunter, Steven Treon

Blood (2025) 146 (Supplement 1): 3611.

https://doi.org/10.1182/blood-2025-3611

Published: 2025

Journal Articles

Stapled BAD BH3 Helices Effectively Target BCL-2 Mutants That Cause Venetoclax Resistance

Thomas M. Deangelo, Utsarga Adhikary, Kyle J. Korshavn, Clara R. Brotzen-Smith, Hyuk-Soo Seo, Kijun Song, Luke Sebastian, Sirano Dhe-Paganon, Thomas E. Wales, Gregory H. Bird, Loren D. Walensky

Blood (2024) 144 (Supplement 1): 7472.

https://doi.org/10.1182/blood-2024-208553

Published: 2024

Journal Articles

Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma

Michael P. Agius, Laura Hevenor, N Connor Payne, Qi Liu, Hyuk-Soo Seo, Romanos Sklavenitis-Pistofidis, Daniel Heilpern-Mallory, Puspalata Bashyal, Michelle P. Aranha, Elizabeth D. Lightbody, Ralph Mazitschek, Sirano Dhe-Paganon, Jun Qi, Irene Ghobrial

Blood (2024) 144 (Supplement 1): 155.

https://doi.org/10.1182/blood-2024-203381

Published: 2024

Journal Articles

Discovery of First-in-Class Small Molecule Inhibitors of the IRF4-PU.1/Spi-B Interaction

Mike P. Agius, Laura Hevenor, N Connor Payne, Ralph Mazitschek, Hyuk-Soo Seo, Sirano Dhe-Paganon, Jun Qi, Irene M. Ghobrial

Blood (2023) 142 (Supplement 1): 3635.

https://doi.org/10.1182/blood-2023-186864

Published: 2023

Journal Articles

Ubiquitin Receptor PSMD4/Rpn10 Is a Novel Therapeutic Target in Myeloma

Ting DU, Yan Song, Arghya Ray, Ruben D. Carrasco, Sirano Dhe-Paganon, Dharminder Chauhan, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 1591.

https://doi.org/10.1182/blood-2021-151377

Published: 2021

Journal Articles

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

Teru Hideshima, Francesca Cottini, Yoshihisa Nozawa, Hyuk-Soo Seo, Hiroto Ohguchi, Mehmet K. Samur, Diana Cirstea, Naoya Mimura, Yoshikazu Iwasawa, Paul G. Richardson, Nikhil C. Munshi, Dharminder Chauhan, Walter Massefski, Teruhiro Utsugi, Sirano Dhe-Paganon, Kenneth C. Anderson

Blood (2017) 129 (10): 1308–1319.

https://doi.org/10.1182/blood-2016-09-738500

Published: 2017

Includes: Supplemental data

Journal Articles

Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform

Joanna S. Yi, MD, Alex Federation, Jun Qi, PhD, Sirano Dhe-Paganon, PhD, Michael Hadler, MSc, Xiang Xu, PhD, Anthony Varca, Roodolph St. Pierre, Scott A. Armstrong, MD PhD, James E. Bradner

Blood (2014) 124 (21): 4811.

https://doi.org/10.1182/blood.V124.21.4811.4811

Published: 2014

Journal Articles

Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells

G. Wei Xu, MD, PhD, Julia I. Toth, PhD, Sara R. da Silva, BSc, Stacey-Lynn Paiva, BSc, Julie L. Lukkarila, PhD, Rose Hurren, Neil Maclean, BSc, Mahadeo A. Sukhai, PhD, Rabindra N. Bhattacharjee, PhD, Carolyn A. Goard, PhD, Bruno C Medeiros, MD, Patrick T. Gunning, PhD, Sirano Dhe-Paganon, PhD, Matthew D. Petroski, PhD, Aaron Schimmer, PhD, MD

Blood (2013) 122 (21): 2527.

https://doi.org/10.1182/blood.V122.21.2527.2527

Published: 2013

Journal Articles

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

Blood (2010) 115 (11): 2251–2259.

https://doi.org/10.1182/blood-2009-07-231191

Published: 2010

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Zanubrutinib and pirtobrutinib (ZAP) but not ibrutinib and pirtobrutinib (IAP) show synergistic tumor cell killing and suppression of BTK and downstream signaling in MYD88 mutated lymphoma cells.

CD20 (MS4A1) mutations are strongly associated with prior chemoimmunotherapy exposure in Waldenström macroglobulinemia and have predicted functional consequences for the development of CD20-directed cellular therapies.

Stapled BAD BH3 Helices Effectively Target BCL-2 Mutants That Cause Venetoclax Resistance

Pharmacological Targeting of IRF4 As a Therapeutic Strategy for Multiple Myeloma

Discovery of First-in-Class Small Molecule Inhibitors of the IRF4-PU.1/Spi-B Interaction

Ubiquitin Receptor PSMD4/Rpn10 Is a Novel Therapeutic Target in Myeloma

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform

Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only